Overall safety
treatment-emergent adverse, deaths
ADVERSE EVENTS, HEPATIC STEATOSIS
ARO-ANG3 was generally well tolerated when administered subcutaneously as a single dose in HPs and repeat doses in HPs and participants with hepatic steatosi. There were no deaths, life-threatening treatment-emergent adverse events (TEAEs) or TEAEs leading to drug discontinuation or premature withdrawal of any participant from the study. There were no treatment-related serious adverse events (SAEs), and most TEAEs were either mild or moderate.ARO-ANG3 was not associated with any consistent pattern of adverse changes in laboratory parameters. There were no reported clinically meaningful declines in platelet count. Plots for total bilirubin versus ALT at peak post-dose values and at the end of the study are presented in Supplementary Figs. 